ASH 2017 | Promising treatment options for relapsed, low grade lymphoma
The 2017 American Society of Hematology (ASH) Annual Meeting, in Atlanta, GA, was an exciting event with results from multiple clinical trials being presented. Here, Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the promising results from combining pembrolizumab with lenalidomide for treating relapsed, low grade lymphoma. While treating Hodgkin and non-Hodgkin lymphoma with checkpoint inhibitors has seen positive results previously, unfortunately there has been less headway made for treating relapsed, low grade lymphoma, which is why these results presented at ASH 2017 will be key for influencing future treatment options. Dr Fowler gives a brief on the work done at MD Anderson Cancer Center, including the combination of monoclonal antibodies with lenalidomide, and the recent phase II study combining rituximab with and pembrolizumab for controlling relapse follicular lymphoma (NCT02446457).
